New form of Roche's Esbriet approved in Europe for lung disorder

ZURICH (Reuters) - Roche said a new Esbriet tablet formulation was approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF), a fatal condition that causes irreversible, progressive scarring of the lungs.